Salah Yehia, Omar Kholoud, Sherif Ahmed, Azzam Sarah
Department of Ophthalmology, Cairo University, Giza, Egypt.
J Ophthalmol. 2019 Sep 26;2019:3904565. doi: 10.1155/2019/3904565. eCollection 2019.
This is a prospective interventional clinical trial to assess the depth of the demarcation line in transepithelial versus epithelium-off accelerated corneal cross-linking (AXL) in keratoconus patients.
This prospective clinical trial was conducted on 40 eyes of 20 patients. Each patient had transepithelial AXL in one eye and epithelium-off AXL in the contralateral eye applying UVA light with an irradiance of 45 mW/cm for 2.4 minutes and 30 mW/cm for 4 minutes. The depth of the demarcation line was measured using anterior segment OCT (Topcon 3D OCT-2000) one month postoperative for both eyes.
The demarcation line was patchy in 50% of the transepithelial AXL eyes, the other half showing a demarcation line at a mean depth of 183 ± 41.6 m. In the epithelium-off AXL technique, the demarcation line was well defined in all cases with a mean depth of 219 ± 27.3 m. There was a statistically significant difference in corneal demarcation line depth between transepithelial and epithelium-off techniques ( = 0.008 and < 0.05). The shallower demarcation line in the transepithelial group suggests that it is less effective.
Based on the depth of the demarcation line, the cross-linking effect of epi-off AXL seems more efficacious than after transepithelial AXL. The future will show if the biomechanical effect will be sufficient to stop progression of keratoconus similarly after standard CXL. This trial is registered with NCT04045626.
这是一项前瞻性干预性临床试验,旨在评估圆锥角膜患者经上皮与去上皮加速角膜交联(AXL)中分界线的深度。
这项前瞻性临床试验对20例患者的40只眼进行。每位患者一只眼接受经上皮AXL,对侧眼接受去上皮AXL,应用紫外线A光,辐照度为45 mW/cm²,照射2.4分钟,以及30 mW/cm²,照射4分钟。术后1个月使用眼前节光学相干断层扫描(Topcon 3D OCT - 2000)测量双眼分界线的深度。
经上皮AXL组50%的眼睛分界线呈片状,另一半眼睛分界线平均深度为183 ± 41.6 μm。在去上皮AXL技术中,所有病例分界线均清晰,平均深度为219 ± 27.3 μm。经上皮与去上皮技术在角膜分界线深度上存在统计学显著差异(P = 0.008,P < 0.05)。经上皮组较浅的分界线表明其效果较差。
基于分界线的深度,去上皮AXL的交联效果似乎比经上皮AXL更有效。未来将表明生物力学效应在标准角膜交联术后是否同样足以阻止圆锥角膜的进展。本试验已在ClinicalTrials.gov注册,注册号为NCT04045626。